Journal article
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Dengue virus is the most serious mosquito-borne viral threat to public health and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent DENVax vaccine contains a molecularly characterised live attenuated dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E structural genes for serotypes 1, 3, and 4 in the DENVax-2 genetic backbone. The researchers aimed to assess the safety and immunogenicity of tetravalent DENVax formulations.
Authors
Languages
- English
Publication year
2014
Journal
The Lancet Infectious Diseases
Volume
9
Type
Journal article
Categories
- Vaccines & delivery devices
Diseases
- Dengue
Countries
- Colombia
Tags
- New vaccine introduction
WHO Regions
- Region of the Americas